Tower Research Capital (TRC)
IGC icon

Tower Research Capital (TRC)’s IGC Pharma IGC Stock Holding History

Tower Research Capital (TRC)’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.51K Buy
27,607
+6,558
+31% +$1.94K ﹤0.01% 4129
2026
Q1 		$5.54K Buy
21,049
+6,657
+46% +$1.85K ﹤0.01% 4109
2025
Q4 		$4.05K Buy
14,392
+4,599
+47% +$1.64K ﹤0.01% 4268
2025
Q3 		$4.08K Sell
9,793
-2,106
-18% -$801 ﹤0.01% 4407
2025
Q2 		$3.64K Sell
11,899
-1,454
-11% -$437 ﹤0.01% 4459
2025
Q1 		$3.81K Buy
13,353
+2,310
+21% +$729 ﹤0.01% 4346
2024
Q4 		$3.71K Buy
11,043
+547
+5% +$205 ﹤0.01% 4608
2024
Q3 		$4.48K Buy
10,496
+2,478
+31% +$993 ﹤0.01% 4532
2024
Q2 		$3.48K Sell
8,018
-5,636
-41% -$2.8K ﹤0.01% 4885
2024
Q1 		$5.46K Sell
13,654
-9,663
-41% -$3K ﹤0.01% 4539
2023
Q4 		$6.53K Buy
23,317
+1,982
+9% +$614 ﹤0.01% 4728
2023
Q3 		$7.66K Buy
21,335
+654
+3% +$234 ﹤0.01% 4446
2023
Q2 		$6.45K Sell
20,681
-114
-0.5% -$37 ﹤0.01% 4703
2023
Q1 		$7K Buy
20,795
+10,703
+106% +$4.01K ﹤0.01% 4741
2022
Q4 		$3K Buy
+10,092
New +$4.12K ﹤0.01% 5195
2022
Q2 		– Sell
-1,364
Closed -$1K – 6270
2022
Q1 		$1K Buy
1,364
+968
+244% +$940 ﹤0.01% 5804
2021
Q4 		$0 Buy
+396
New +$531 ﹤0.01% 6330
2021
Q1 		– Sell
-28,742
Closed -$45K – 5535
2020
Q4 		$45K Buy
28,742
+23,987
+504% +$35.4K ﹤0.01% 3213
2020
Q3 		$5K Buy
+4,755
New +$4.83K ﹤0.01% 4357
2015
Q3 		– Sell
-43
Closed – – 4349
2015
Q2 		$0 Hold
43
– – ﹤0.01% 4672
2015
Q1 		$0 Sell
43
-91
-68% -$49 ﹤0.01% 4643
2014
Q4 		$0 Hold
134
– – ﹤0.01% 4309
2014
Q3 		$0 Hold
134
– – ﹤0.01% 4621
2014
Q2 		$0 Buy
134
+27
+25% +$31 ﹤0.01% 4309
2014
Q1 		$0 Buy
107
+93
+664% +$81 ﹤0.01% 4659
2013
Q4 		$0 Buy
14
+7
+100% +$6 ﹤0.01% 4682
2013
Q3 		$0 Sell
7
-218
-97% -$272 ﹤0.01% 4670
2013
Q2 		$0 Buy
+225
New +$472 ﹤0.01% 3943

Other funds holding IGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $145M AUM 29.71% 1-Year Est. Return

Tower Research Capital (TRC)'s IGC Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its IGC Pharma (IGC) stake by 31% in Q2 2026, buying an estimated $1.94K and bringing the position to 27,607 shares worth $7.51K. The position accounts for ﹤0.01% of the portfolio, ranked #4129.

Tower Research Capital (TRC) first reported a position in IGC in Q2 2013 and has held it in 28 quarters since. The position peaked at $45K in Q4 2020. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

  • Tower Research Capital (TRC) held 27,607 shares of IGC Pharma worth $7.51K as of Q2 2026.
  • Tower Research Capital (TRC) bought 6,558 IGC Pharma shares in Q2 2026, an estimated $1.94K.
  • IGC Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4129 holding.
  • Tower Research Capital (TRC) first reported a position in IGC Pharma in Q2 2013 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s IGC Pharma position peaked at $45K in Q4 2020.
  • 36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.